Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6069803 | Journal of the American Academy of Dermatology | 2016 | 7 Pages |
Abstract
Patients with HIV and AIDS are living longer because of advancements in antiretroviral therapy. These patients are often susceptible to debilitating inflammatory disorders that are refractory to standard treatment. We discuss the relationship of tumor necrosis factor-alpha and HIV and then review 27 published cases of patients with HIV being treated with tumor necrosis factor-alpha inhibitors. This review is limited because no randomized controlled trials have been performed with this patient population. Regardless, we propose that reliable seropositive patients, who are adherent to medication regimens and frequent monitoring and have failed other treatment modalities, should be considered for treatment with tumor necrosis factor-alpha inhibitors.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Stephanie M. MD, Laura BA, Kanwaljit MD, Eve MD, PhD,